Exploration of Intra-individual Variability of Exposure to Emtricitabine and Lamivudine in Hair With a View to Validating the Value of This Matrix as a Diagnostic Tool for Partial and/or Total Non-compliance With Antiretroviral Treatment

Treatment adherence is defined by compliance with the dosage schedule (i.e., dose per dose and number of doses per day), as well as the duration of administration (i.e., number of days during which the dosage schedule must be followed).
Treatment adherence determines the therapeutic efficacy and the absence of toxicity of the prescribed medication. However, this adherence is far from being respected even by patients with serious pathologies such as patients living with HIV (PLWHIV). However, among PLWHIV, non-adherence is a significant source of virological failure and is difficult to assess because it is most often based on what the patient reports to their doctor. A currently used approach consists of determining the drug concentration in the blood and possibly that of its metabolite(s). However, determining a drug's blood concentration presents two major pitfalls: (i) it is necessary to take a blood sample, which remains an invasive procedure for the patient; (ii) for the vast majority of drugs, if the patient scrupulously adheres to the dosage schedule a few days before the blood sample is taken, the drug concentration is most often within the expected range. Therefore, a concentration in the reference range does not exclude partial or even total non-compliance between two medical visits. Saliva is a more easily accessible matrix than blood. However, the same representativeness problem is encountered due to the fact that saliva is in almost instantaneous equilibrium with blood.
Urine could be used to assess compliance. However, this requires multiple urine collections between two doses. This constraint is not compatible with the organization of clinical services. The objective is to determine intra-individual variability in the amount of antiretroviral (ARV) in different segments of the same strand of hair during periods of full treatment adherence.
This objective is preliminary to the use of hair as a tool for detecting treatment non-adherence in patients.
Two reference antiretroviral molecules will be documented: Emtricitabine and Lamivudine, as they are present, one or the other, in the majority of antiretroviral combination strategies.

开始日期2025-07-03

申办/合作机构

Toulouse University Hospital

NCT07058974

/ Not yet recruiting临床1期IIT

A Phase 1b, Multi-cohort Clinical Trial Assessing Safety and Feasibility of Exercise and Spermidine Administered in Conjunction With Lamivudine (RTi) or Rapamycin (mTORi) to Assess Impact on Dynamic Changes of Inflammation and Aging

This is a study assessing the feasibility of performing an anti-aging intervention which is a combination of an exercise regimen, spermidine supplementation, and either rapamycin or lamivudine.

开始日期2025-07-01

申办/合作机构

Icahn School of Medicine at Mount Sinai

NCT06428045

/ Recruiting临床1期IIT

Synergistic Treatment With Antiretrovirals and Laser Interstitial Thermal thErapy (STARLITE) for Unresectable High-Grade Gliomas: A Phase 1 Study

The purpose of this study is to determine whether newly diagnosed high-grade glioma(s) that cannot be removed surgically change as a result of the study treatment; and to identify and evaluate the potential side effects (good and bad) of the study treatment in patients with newly diagnosed high-grade glioma(s) that cannot be removed surgically.

开始日期2025-04-15

申办/合作机构

University of Miami

[+1]

100 项与拉米夫定相关的临床结果

登录后查看更多信息

100 项与拉米夫定相关的转化医学

登录后查看更多信息

100 项与拉米夫定相关的专利（医药）

登录后查看更多信息

13,873

项与拉米夫定相关的文献（医药）

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Treatment persistence among treatment-experienced people with HIV switching to integrase strand transfer inhibitor–based antiretroviral regimens

Article

作者: Chen, Megan ; de Boer, Melanie ; Trom, Cassidy ; Chuo, Ching-Yi ; Christoph, Mary J. ; Zachry, Woodie

AIMS:

Low rates of persistence are associated with poor outcomes in people with HIV (PWH). This retrospective cohort study assessed treatment persistence as measured by time to treatment switch in treatment-experienced (TE) PWH initiating integrase strand transfer inhibitor (INSTI)-based regimens.

METHODS:

United States prescription claims and medical history data from the IQVIA Longitudinal Access and Adjudication Dataset between January 1, 2018, and August 31, 2023, were analyzed. TE PWH with ≥1 prescription claim for initiation of an INSTI-based antiretroviral regimen during the index period (January 1, 2020, to December 31, 2022) were included. Descriptive analyses of demographic and comorbidity variables were performed, stratified by regimen. Kaplan-Meier analysis was used to evaluate time to subsequent treatment switch in the overall population and among PWH aged ≥50 years, those receiving Medicare, and those with mental health conditions or substance use disorders.

RESULTS:

Overall, 29,348 TE PWH were included. The majority of INSTI-based regimen initiations were for bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (61%; n = 17,917), followed by dolutegravir/lamivudine (27.4%; n = 8034) and cabotegravir + rilpivirine (7.4%; n = 2186). A subsequent switch occurred in 3341 (11.4%) PWH. Risk factors for switch included female sex, Medicare/Medicaid coverage, and higher Charlson Comorbidity Index scores. B/F/TAF was associated with the fewest subsequent switches (9.2%; n = 1656) and was significantly less likely than any other regimen to lead to a subsequent switch, either in the overall population or in the three at-risk subgroups.

LIMITATIONS:

No data are available to determine the underlying reasons for initial treatment choice or subsequent treatment switch.

CONCLUSIONS:

This study provides evidence for greater treatment persistence with B/F/TAF versus other INSTI-based regimens. Unlike prior studies that focused on treatment-naïve individuals, this analysis uniquely evaluates persistence among treatment-experienced PWH initiating newer INSTI-based regimens.

2025-12-31·Global Health Action

Low-level viremia in people with HIV in Ethiopia is associated with subsequent lack of viral suppression and attrition from care

Article

作者: Abdissa, Alemseged ; Björkman, Per ; Abdulahi, Ilili Jemal ; Reepalu, Anton ; Elvstam, Olof ; Medstrand, Patrik

BACKGROUND:

Low-level viremia during antiretroviral therapy (ART) has been associated with inferior outcomes, but knowledge on the impact of low-level viremia in the current era of dolutegravir-based ART in low-income countries is limited.

OBJECTIVE:

To investigate whether low-level viremia predicts virologic non-suppression and attrition from care in people with HIV receiving ART in Ethiopia.

METHODS:

We included people receiving ART at public health facilities in an urban area in central Ethiopia and categorized persons with ≥1 available viral load 2019-2020 as having either suppression (<150 copies/mL) or low-level viremia (151-1,000 copies/mL); people with >1,000 copies/mL were excluded. We used multivariable logistic regression adjusted for age, sex, ART regimen, type of health facility, and duration of ART to analyze the associations between viremia category and incidence of unsuppressed viral load (>1,000 copies/mL) and attrition from care (death or loss to follow-up) during 3 years of follow-up.

RESULTS:

Among 12,165 participants, the median age was 44 years, 64.2% were female, and 89.1% received tenofovir/lamivudine/dolutegravir. Of the study population, 11,959 (98.3%) had suppression and 206 (1.7%) had low-level viremia. Over 3 years of follow-up, 2.2% of participants with suppression and 11.3% with low-level viremia had unsuppressed viral load. Low-level viremia was associated with both unsuppressed viremia (adjusted odds ratio [aOR], 3.7; 95% confidence interval [CI], 2.2-6.2) and attrition (aOR, 3.4; 95% CI, 1.7-6.6).

CONCLUSION:

Among Ethiopian people with HIV receiving ART, low-level viremia predicted subsequent virologic non-suppression and attrition from care, supporting current recommendations for heightened attention to low-level viremia in ART recipients.

2025-12-31·ANNALS OF MEDICINE

24-month outcomes after switching to Dolutegravir/Lamivudine in people living with HIV and HBcAb positivity at the Beijing Ditan Hospital in China

Article

作者: Zhao, Hongxin ; Biao, Ruojia ; Liu, Ying ; Chen, Jing ; Fu, Jiantao

BACKGROUND:

Dolutegravir/lamivudine (DTG/3TC) is a recommended therapy regimen for hepatitis B surface antigen (HBsAg)-negative people living with HIV (PLWH) who have achieved HIV virological suppression or are treatment-naïve. However, this may overlook the impact of occult hepatitis B infection on HIV suppression, which mainly present as hepatitis B core antibody (HBcAb) positive but HBsAg negative. We aim to assess the effect of HBcAb positivity on HIV suppression among PLWH who had switched to DTG/3TC.

METHODS:

A retrospective study was conducted including 127 HBcAb-positive and 474 HBcAb-negative PLWH (all were HBsAg negative) who had switched to DTG/3TC at the Beijing Ditan Hospital in China. HIV-RNA suppression was compared pre-switch (not baseline), at switch, and at 12&24 months post-switch, across three categories: (1) target not detected (TND); (2) HIV RNA < 40 cp/mL; (3) blip. Virological suppression included TND and HIV RNA < 40 cp/mL. Epidemiological (gender, age) and clinical data (CD4 count, HIV viral load, etc.) were extracted from the hospital information system. A p-value < 0.05 was considered statistically significant.

RESULT:

HBcAb-positive PLWH were older at DTG/3TC switch (median age: 41 vs. 36 years old, p < 0.001) and had lower nadir CD4 counts (median nadir CD4 counts: 255 vs. 295, p = 0.011). No difference in TND and HIV RNA < 40 cp/mL was present in the two groups at the switch (HBcAb-positive and -negative: 86.6% vs. 88.8%, 12.6% vs. 10.5%, p = 0.789). Similar HBcAb-positive compared with -negative PLWH resulted in TND at 12&24 months post-switch: 91.4% vs. 91% (p = 0.522) and 88.4% vs. 92.7% (p = 0.249), respectively. Consistent result was observed in HIV RNA < 40 cp/mL.

CONCLUSION:

In the 24-month follow-up after switching to DTG/3TC, HBcAb positivity was not significantly associated with HIV virological suppression.

235

项与拉米夫定相关的新闻（医药）

2025-08-13

·健识局

“中国版吉利德”，一个月内股价暴涨3倍

A股医药板块最近两月上演了一出狂飙大戏。广生堂在7月涨幅近220%，8月又再涨近20%，股价从7月初的36元暴涨至近137元。短时间内有这样的涨幅，今年大概只有“妖股”舒泰神可以媲美了。市场看好的逻辑是：广生堂手上有一款双药组合，被传有希望治愈乙肝。广生堂原本是一家主营肝病仿制药的企业，2015年进行仿转创转型，提出了乙肝临床治愈的“登峰计划”。今年7月，公司两款乙肝创新药GST-HG141和GST-HG131双双取得临床进展，进一步引爆了市场。值得一提的是，今年1月，广生堂的大股东将所持约5%股份以不足2亿元的价格转让给圆山基金。圆山基金最大的出资方是同在福建的老牌企业片仔癀。算下来，片仔癀靠着广生堂，近期已经浮盈超3亿元。乙肝治愈神话广生堂是福建省第一家上市医药企业，早年以茵白肝炎胶囊、灵芝胶囊等中成药起家，后来入局肝病仿制药领域，曾靠拉米夫定、阿德福韦酯、恩替卡韦等三款乙肝仿制药叱咤国内肝病市场。 2015年，广生堂开始决定向创新药转型，此后2016-2024年间，公司累计研发支出近10亿元，远超行业平均水平。公司重点押注在乙肝创新药物的开发上。这期间歪打正着，广生堂在2023年11月成功上市了抗新冠口服药“泰中定”，成为公司首款上市的创新药产品，只可惜新冠疫情转瞬而去，这款药物只为广生堂带来了口碑。广生堂要好好经营的还是乙肝市场。中国有8700万乙肝感染者，对应的是一个千亿级的药物市场。广生堂2015年决定开发乙肝创新药时，是经过了充分准备的，公司遍访中国乙肝领域顶级专家，给自己设定了乙肝药物组合策略的“登峰计划”。广生堂目前的两款潜在重磅单品：乙肝核心蛋白抑制剂GST-HG141、乙肝表面抗原抑制剂GST-HG131，都是与药明康德合作开发的。目前全球范围内尚无同类产品上市。基于这两款药品，广生堂提出针对乙肝治愈的“全口服三联疗法”，即这两款药加上核苷类药物。据称，这一疗法是全球首个进入临床的乙肝治愈方案，有望打破现有治疗只能抑制病毒、无法根治的局限，成为全球首个口服治愈方案。警惕估值泡沫今年7月10日，广生堂公告称，GST-HG131被纳入突破性治疗品种名单。去年12月，另一款GST-HG141已经先一步获得突破性治疗认定。 7月25日，广生堂再发公告，称GST-HG141的三期临床试验已完成首例受试者入组给药。这一系列消息刺激了广生堂的股价一路上涨。乐观者开始预测，如果按每半年1.2万元的疗程定价，这一药物组合的峰值销售额有望达到630亿到840亿元，届时广生堂可能会成为“中国版吉利德”。也有冷静者分析，乙肝治愈的难度很大，罗氏等巨头药企都在这一领域多次折戟。而且，这个赛道的竞争也在愈演愈烈。数据显示，全球在研乙肝新药管线近200条，不仅有GSK、吉利德等跨国企业深度参与，国内企业如恒瑞医药、东阳光等也纷纷入局。广生堂目前进度较快的GST-HG141的III期临床试验也需至少2-3年，后期临床结果仍未可知。但是眼前广生堂就要面临最困难的时刻：创新药需要持续投入，集采影响公司的抗乙肝病毒药物收入。广生堂已经连续4年亏损，累亏超6亿元，现在账上只剩1.2亿元，短期债务超过3亿元。今年4月初，广生堂发布定增议案，拟融资近10 亿元，其中5.98亿元拟投入“创新药研发项目”，目前仍未成行。截至8月13日收盘，广生堂市净率已经突破65，远超医药行业平均水平数十倍。广生堂的乙肝治愈梦想，还需要更坚实的临床数据来支撑。撰稿丨李傲编辑丨江芸贾亭运营丨晨曦插图丨视觉中国声明：健识局原创内容，未经许可请勿转载 2025医保国谈最新进展：80个品种同时通过医保、商保形式审查靠集采闷声发大财，福建药企带着14款仿制药赴港IPO 首个国产度拉糖肽注射液获批上市

突破性疗法申请上市IPO临床3期

2025-08-05

·化学经纬

陈芬儿院士课题组综述：用于治疗HBV感染的核苷类药物的合成

乙型肝炎病毒（HBV）是全球关注的重大健康问题，其特点是可能引发急性和慢性肝病。尽管已经有了有效的疫苗和治疗方法，但在慢性感染的管理方面仍然存在巨大的差距，尤其是在中国这样受感染人数达数百万的地区。在此，陈芬儿课题组深入探讨了拉米夫定、阿德福韦、泰诺福韦、恩替卡韦和替比夫定等临床抗乙肝病毒药物的合成，重点介绍了各种合成策略。 1）拉米夫定（Lamivudine）作为代表性药物，其合成需解决双手性中心构建难题，研究者通过动态动力学拆分（产率80%）、绿色糖基化（如ZrCl₄催化）及连续流技术（产率提升至40%）优化工艺，并利用脂肪酶CAL B实现立体选择性合成； 2）阿德福韦（Adefovir）的传统路线依赖昂贵试剂MTB，改进后采用叔丁醇钠或碘化物试剂简化流程； 3）泰诺福韦（Tenofovir）及其前药（TAF和TDF）则通过连续流技术高效制备关键中间体(R)-碳酸丙烯酯，并借助工程化脱氢酶实现不对称还原。 4）恩替卡韦（Entecavir）因强效低耐药性备受关注，其合成从早期十步法反应（总产率18%）发展为分子内氧化腈环加成、无环前体合成等创新方法，工业上更以D-葡萄糖或(S)-香芹酮为原料降低成本。 5）替比夫定（Telbivudine）的合成依赖于关键的中间体 L-chlorosugar，通过羰基迁移或磷酸氧化物等方法合成，实现高β-选择性。未来，不对称催化（如金属/生物催化剂）和流动化学的结合是增强抗 HBV 药物合成的一条有前途的途径。流动化学提供了一个可微调的动态环境，能为金属催化剂或酶促进不对称反应提供最佳条件。这种协同作用不仅提高了反应产率和选择性，还最大限度地减少了合成所需的时间和资源。图1. 药物的化学结构（图片来源：Green Synth. Catal.）图2. 拉米夫定的部分合成策略（图片来源：Green Synth. Catal.）图3. 阿德福韦的广泛使用的合成路线（图片来源：Green Synth. Catal.）图4. 泰诺福韦的部分合成策略（图片来源：Green Synth. Catal.）图5. 恩替卡韦的部分合成策略（图片来源：Green Synth. Catal.）图6. 恩替卡韦合成示意图总结（图片来源：Green Synth. Catal.）图7. 替比夫定的部分合成策略（图片来源：Green Synth. Catal. Synthesis of nucleoside drugs for the treatment of HBV infection: An updated review. Green Synth. Catal., 2025, https://doi.org/10.1016/j.gresc.2025.06.001.

疫苗临床研究寡核苷酸

2025-08-05

·药事纵横

恒瑞GSK资本局：解锁中国药企出海新密码

三年三次深度绑定，恒瑞与GSK的反复联手绝非偶然。当中国创新药企遭遇国际化瓶颈，跨国巨头面临专利悬崖与研发成本高企，一场重构全球医药分工的精密布局悄然展开。从"中间商"溢价套现到股权绑定，再到平台化授权，双方以资本为纽带各取所需。这场看似双赢的合作背后，是战略互补的必然选择，还是风险转嫁的权宜之计？三年三次“握手” 恒瑞与GSK的互动堪称精彩棋局，2023年，恒瑞迈出了关键的第一步——借壳AiolosBio。恒瑞关联方在美国成立OneBio公司（后更名AiolosBio），并于2023年8月以2500万美元首付+10.25亿里程碑款将恒瑞TSLP单抗SHR-1905（代号AIO-001）的海外权益授予AiolosBio。AiolosBio宛如资本运作的高手，成立短短5个月内便完成2.45亿美元A轮融资，估值迅速抬升。2024年1月，GSK以14亿美元收购AiolosBio，恒瑞间接实现资产增值。虽然原始授权收益上限仅10.25亿，但通过这一系列资本化运作，收益放大至14亿。然而，恒瑞未持股AiolosBio，导致增值收益流失，这也为后续的合作策略调整埋下伏笔。 2024年，恒瑞与GSK的合作模式迎来升级，进入“绑权”阶段。恒瑞联合贝恩资本等成立Hercules（后更名Kailera），并注入GLP-1管线海外权益，恒瑞持股19.9%。这一持股安排意义深远，使得恒瑞能够共享资本溢价，与Aiolos模式形成鲜明对比。同时，Hercules引入明星管理层，如吉利德前CEO担任董事，强化了资本信任。值得注意的是，融资方中包含GSK产业基金关联机构，让GSK间接介入，为后续的深度合作与并购埋下了伏笔。时间来到2025年，恒瑞与GSK的合作再度升华，实现了“直连”。恒瑞将PDE3/4抑制剂HRS-9821及11个早期项目打包授权给GSK，获得5亿美元首付，以及高达120亿的里程碑款与销售分成。此次合作从之前的间接资本化彻底转向直接捆绑GSK的研发资源，合作领域覆盖呼吸、肿瘤、自免三大核心领域。这不仅是交易规模的扩大，更是合作模式的质变，标志着双方深度捆绑的开始。双赢棋局这场持续三年的合作盛宴，表面上是资本的游戏，实则蕴含着双方深层次的战略考量，是一场双赢的精心布局。恒瑞作为中国创新药的领军企业，虽然在研发上成果丰硕，但在国际化进程中面临着诸多挑战，尤其是在欧美市场的商业化渠道建设上存在短板。而GSK在呼吸领域拥有强大的市场地位，市占率超25%，其广泛的销售网络和成熟的市场推广经验，正是恒瑞所急需的。通过与GSK合作，恒瑞能够借助其渠道，加速自身管线产品出海，实现国际化破局。海外Ⅲ期临床成本高昂，通常超过5亿美元，这对于任何药企来说都是巨大的负担。恒瑞将部分项目授权给GSK，成功转移了研发风险。以此次打包授权的12个项目为例，研发过程中的不确定性被分散，恒瑞无需独自承担可能的失败成本。从财务角度看，三次合作给恒瑞带来了累计超200亿美元的潜在收益。这些资金如同及时雨，为恒瑞的研发注入了强大动力，有力支撑了其创新投入，让恒瑞在新药研发的道路上能够持续深耕。对于GSK而言，与恒瑞的合作同样具有重要战略意义。GSK的核心产品Trelegy专利到期，面临着专利悬崖的困境，急需新的产品来填补COPD领域的空白，维持市场竞争力。恒瑞的PDE3/4抑制剂HRS-9821等项目，恰好为GSK提供了绝佳的机会，有望成为其新的利润增长点。中国的研发成本仅为欧美的30%-50%，这使得GSK能够以较低的成本获取创新项目。此次5亿首付锁定12个项目，单项目成本仅0.42亿，远低于自研投入。同时，GSK通过选择权机制，在I期数据的基础上过滤失败项目，仅对达标管线支付高额里程碑款，有效降低了研发风险。合规博弈论在商业世界中，道德与利益的天平常常难以平衡，恒瑞与GSK的合作便是这一现象的典型例证。回顾历史，GSK在2014年深陷行贿丑闻，系统性地向中国医生行贿，虚高药价，如贺普丁在中国定价142元，而在韩国仅18元，最终被罚30亿元人民币。这一事件在当时引起轩然大波，严重损害了GSK的企业形象和市场信誉。恒瑞同样未能摆脱争议的阴影。2023年8月，网传恒瑞办事处被查封，尽管公司紧急辟谣，但未公开调查结果，此事依然给恒瑞蒙上了一层阴影，使得恒瑞的合规问题备受关注。然而，令人意外的是，这些历史污点并未阻碍恒瑞与GSK的合作脚步。双方似乎达成了一种默契，在利益的驱使下，选择将过往的争议放在一边，携手共进。为了规避潜在的合规风险，双方采取了一系列巧妙的策略。在研发与销售环节，恒瑞主要负责早期研发，将风险较高、不确定性较大的前期工作承担起来。而GSK凭借其丰富的海外经验和成熟的运营体系，承担海外临床及销售合规责任。这种明确的分工使得双方在各自擅长的领域发挥优势，同时也将合规风险进行了有效切割。通过海外公司Aiolos和Kailera持有资产，也是双方规避中美监管冲突的重要手段。这些海外实体就像是一道缓冲带，将恒瑞与GSK之间的合作资产与复杂的地缘政治和监管环境隔离开来。即使中美之间存在监管政策的差异和冲突，也能在一定程度上避免对合作项目的直接冲击，确保合作的稳定性和持续性。是陷阱还是通途恒瑞与GSK的合作虽然看似前景广阔，但在表面的繁荣之下，隐忧已逐渐浮现，为这场合作的未来增添了不确定性。恒瑞过度依赖GSK的风险不容小觑。在Aiolos交易中，由于恒瑞未持股，导致增值收益大量流失，这一教训凸显了过度依赖外部合作可能带来的定价权削弱问题。若恒瑞在后续合作中持续处于被动地位，未来可能在收益分配、项目决策权等方面丧失话语权。对于Kailera，若其未来被GSK收购，恒瑞仅持有的19.9%股权能否匹配资产价值存在很大疑问。一旦股权价值被低估，恒瑞将在这场资本游戏中遭受损失。 GSK同样面临着整合挑战。恒瑞授权的PDE3/4抑制剂HRS-9821，虽然具有潜力，但市场竞争异常激烈，默沙东的同类产品已经在市场上形成了强大的竞争态势，对HRS-9821构成了巨大威胁。这可能导致HRS-9821的市场份额受限，销售分成不及预期，从而影响GSK的收益。12个早期项目由于处于研发早期，本身就伴随着较高的失败率。部分靶点可能在临床试验中失败，不仅会浪费大量的研发资源和时间，还可能拖累GSK的整体研发进度和收益。从行业层面看，恒瑞与GSK合作中的一些操作，如频繁的更名、通过SPV持有资产等，使得资产归属变得模糊，这极易引发监管审查。美国的《反托拉斯法》等相关法规，对于此类可能影响市场竞争、造成垄断的行为有着严格的监管。一旦被认定存在垄断嫌疑或违规操作，合作项目将面临巨大的法律风险和监管压力。恒瑞与GSK过去的贿赂污点，使得它们之间的合作依赖于“利益压倒合规”的逻辑。在社会对企业道德和合规要求日益严格的背景下，这种模式显然难以持续。一旦舆论压力增大或监管加强，合作双方将面临巨大的声誉风险和法律风险，合作的稳定性将受到严重挑战。结语恒瑞与GSK的反复联姻，映射出全球医药产业链的重构浪潮——中国药企以研发效率为筹码，跨国巨头以渠道为杠杆，在专利悬崖与出海困局中抱团取暖。然而，资本魔术无法掩盖根本矛盾：当"灰色历史"遭遇严监管趋势，当管线失败风险对冲分成收益，这场精密布局终将面临可持续性考验。真正的破局点，或许在于从"利益优先"转向"价值创造"。中国药企的国际化进阶，需要的不仅是资本术，更是直面合规与创新的硬仗。药事纵横投稿须知：稿费已上调，欢迎投稿

并购临床3期引进/卖出高管变更

100 项与拉米夫定相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00353	拉米夫定	J05AF05	DB00709

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
乙型肝炎	中国	GSK Plc	1999-03-08
慢性乙型肝炎	美国	GSK Plc	1998-12-08
HIV感染	美国	ViiV Healthcare Co.	1995-11-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
淋巴瘤	临床2期	美国	GSK Plc	2015-12-01
非霍奇金淋巴瘤	临床2期	美国	GSK Plc	2015-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03311945 (CTgov)	临床3期	HIV血清阳性	33	Lamivudine+raltegravir	糧遞蓋積窪積繭遞夢蓋 = 餘願憲廠築憲鬱糧簾鹹簾遞獵範積鹹願憲製憲 (淵願願鏇範製築鹽繭簾, 遞積鏇蓋襯築壓觸糧襯 ~ 觸壓窪醖製積餘積艱願) 更多	-	2025-07-18
NCT02652793 (CTgov)	N/A	代谢性骨病 \| HIV感染	31	ATV+3TC+RTV	艱醖淵獵積糧淵願網製(壓簾顧夢積築齋夢窪願) = 網築蓋糧鏇積簾鏇衊齋鑰選鏇簾構壓廠選構鑰 (糧夢襯壓顧壓壓餘願齋, 0.030) 更多	-	2025-07-02
NCT02150993 (FIT-2, Pubmed) 人工标引	临床2期	HIV感染一线	210	Tenofovir-boEmtricitabineirLamivudineZidovudine	夢顧獵獵蓋網繭艱顧鏇(鏇簾醖獵構製衊淵選鹹) = 醖顧繭夢獵壓選選壓蓋積蓋衊鬱鑰簾網選膚襯 (憲遞鹹鹹衊衊獵衊窪簾 ) 更多	积极	2024-06-01
NCT02150993 (FIT-2, Pubmed) 人工标引	临床2期	HIV感染一线	210	tenofovirirEmtricitabineLamivudine	積願艱窪願網簾蓋製壓(獵蓋夢壓鏇鹹鏇齋鬱願) = 襯餘簾糧膚夢蓋積顧襯壓築鑰壓鹹醖範膚鬱簾 (觸壓壓獵糧顧遞餘鑰餘, 47 ~ 66) 更多	积极	2024-06-01
Pubmed 人工标引	临床4期	HIV感染	229	Dolutegravir+Lamivudine+Tenofovir Disoproxil Fumarate	憲鬱顧糧網糧糧繭夢製(繭簾構窪網觸膚蓋願範) = 389 AEs were reported from 58% of patients. Of these, 61 were related to study treatment. 鹹簾壓蓋餘衊鹹構構齋 (遞構遞鬱膚簾鏇憲繭廠 ) 更多	积极	2022-08-10
IAS2022	N/A	-	787	dolutegravir/lamivudine (DTG/3TC)	構製膚遞齋窪遞蓋壓築(齋窪膚選構鹽鬱膚網鏇) = 範製壓觸壓範艱蓋遞鹽廠製蓋鏇網蓋鏇齋壓網 (鑰築鹹醖壓築鏇鏇網鑰 ) 更多	-	2022-01-01
IAS2022	N/A	-	787	bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC)	構製膚遞齋窪遞蓋壓築(齋窪膚選構鹽鬱膚網鏇) = 觸顧鬱鹹窪鹹顧積齋遞廠製蓋鏇網蓋鏇齋壓網 (鑰築鹹醖壓築鏇鏇網鑰 ) 更多	-	2022-01-01
TANDEM study (IAS2022)	N/A	HIV感染	469	DTG/3TC	遞憲鏇鑰夢鏇夢襯鹹築(壓鹽壓窪範鬱構夢齋壓) = 廠鹽糧顧齋鹹簾醖鹽蓋製衊繭鹽願積糧獵憲範 (築齋築蓋鏇糧選壓鏇廠 ) 更多	-	2022-01-01
ANRS QUATUOR (IAS2022)	N/A	HIV感染	42	Intermittent doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF)	選襯遞鏇蓋積鹽淵壓襯(蓋製艱遞選膚築餘衊齋) = 艱遞廠鑰壓鬱願蓋網淵餘窪蓋淵餘築製膚鹹艱 (糧窪淵顧鬱鬱繭製構餘, 77.4 ~ 97.3) 更多	积极	2022-01-01
NCT02384395 (PHI-05, CTgov)	N/A	HIV感染	40	Dolutegravir 50 mg+Abacavir 600 mg+Lamivudine 300 mg	蓋願鹽膚選範蓋壓網廠 = 遞醖築選築築製淵願築築顧簾蓋蓋顧壓夢窪觸 (餘餘蓋糧醖蓋鹹壓壓壓, 蓋遞餘鬱獵餘築鬱憲鏇 ~ 製蓋選壓糧積顧願鑰繭) 更多	-	2021-11-22
NCT01818258 (IMPAACT P1092, CTgov)	临床4期	营养不良 \| HIV感染	52	Zidovudine+Lamivudine+Lopinavir/Ritonavir (Severe Malnutrition)	製廠憲範餘壓積觸簾鑰(餘繭蓋齋衊憲鬱膚築製) = 壓淵顧夢鬱製顧積糧鏇壓壓遞積膚膚鬱鬱鑰繭 (顧衊鹹遞選衊遞膚糧構, 簾醖鏇齋網觸簾遞夢鹽 ~ 積鑰壓鹽築願願願繭繭) 更多	-	2021-08-12
NCT01818258 (IMPAACT P1092, CTgov)	临床4期	营养不良 \| HIV感染	52	Zidovudine+Lamivudine+Lopinavir/Ritonavir (Normal Nutrition/Mild Malnutrition)	製廠憲範餘壓積觸簾鑰(餘繭蓋齋衊憲鬱膚築製) = 選構夢餘艱醖齋觸醖願壓壓遞積膚膚鬱鬱鑰繭 (顧衊鹹遞選衊遞膚糧構, 夢窪蓋顧構願網壓蓋齋 ~ 鏇構蓋積齋範積衊鹹鏇) 更多	-	2021-08-12
NCT01620944 (CTgov)	临床3期	HIV感染	3	FTC+Tenofovir+Atazanavir+emtricitabine+TDF+ritonavir (Arm A)	醖廠獵鏇衊網積遞淵糧(鏇淵觸製簾襯淵構鹹鏇) = 鹹鹽憲餘夢衊繭築繭襯襯鹽齋鑰膚衊齋願積齋 (範淵網願選窪窪餘遞觸, 醖範淵夢窪築膚鏇醖鹽 ~ 壓鹹窪夢簾夢夢積衊網) 更多	-	2021-08-06
NCT01620944 (CTgov)	临床3期	HIV感染	3	RTVHS+Atazanavir+3TC+Lamivudine+ritonavir (Arm B)	醖廠獵鏇衊網積遞淵糧(鏇淵觸製簾襯淵構鹹鏇) = 製淵餘糧鏇廠顧窪範簾襯鹽齋鑰膚衊齋願積齋 (範淵網願選窪窪餘遞觸, 窪鹽遞獵糧範齋製窪觸 ~ 獵襯蓋衊積簾壓觸廠構) 更多	-	2021-08-06